Evidence Hub

Antitubercular Treatment-induced Psychosis: A Systematic Review and Recommendations

Shobhit Jain, Harjeet Kaur Kapoor, Pradeep Kumar, Vinod Verma, Ajeet Kumar, Amit Singh

Journal of the Indian Medical Association, 2026

Abstract

Review ARticle• What is the role of combining both strategies?• Should the offending drug be reintroduced after symptom resolution? IntroductIonTuberculosis (TB) remains one of the top 10 causes of death globally, 1 with India bearing the highest burden, accounting for a quarter of global TB cases and a third of related deaths. 2 While first-line antitubercular drugs (FLDs) such as isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin are used to treat drug-sensitive TB, cases of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) require secondline drugs (SLDs) such as kanamycin, levofloxacin, cycloserine, fluoroquinolones, ethionamide, capreomycin, p-aminosalicylic acid, moxifloxacin, clofazimine, linezolid, high-dose isoniazid, and amoxicillin-clavulanic acid.Many of these agents are known to cause neuropsychiatric side effects, including psychosis, yet the literature guiding the management of antitubercular drug-induced psychosis (ATDIP) remains sparse.This review evaluates the available literature to provide practical guidance for clinicians managing ATDIP.

How strong is the evidence?

Evidence Hub reads this as a systematic review. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free